Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE®
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 124.83 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $124.83 | 52 Week High | $18.39 | |||
| Open | $124.83 | 52 Week Low | $6.96 | |||
| Day High | $124.83 | P/E | N/A | |||
| Day Low | $124.83 | EPS | $-0.58 | |||
| Volume | 81,679 | |||||
